High Velocity Stocks: LightPath Technologies (NASDAQ:LPTH), Revlon (NYSE:REV), United States Steel Corp. (NYSE:X), Omeros Corporation (NASDAQ:OMER)

LightPath Technologies, Inc. (NASDAQ:LPTH) ended the last trading day at $1.55. Company weekly volatility is calculated as 7.06% and price to cash ratio as 21.46. LightPath Technologies, Inc. (NASDAQ:LPTH) showed a weekly performance of -7.19%.

LightPath Technologies, Inc. (LightPath) manufactures optical components and higher-level assemblies, including precision molded glass aspheric optics, precision molded infrared molded optics, isolators, fiber-optic collimators, GRADIUM glass lenses and other optical materials used to produce products that manipulate light.

LightPath Technologies(NASDAQ:LPTH) announced the earnings results for Fiscal Year 2015 and Q4. The results came in during After-hours on Sep 22, 2015. Company reported revenue of $4.51M. The estimated revenue was of $3.20M. Earnings per share were $0.03. The reported EPS was above estimates by $0.02 or 200.00%. Analysts had estimated an EPS of $0.01.

On 25 September, Revlon, Inc. (NYSE:REV) shares fell -2.49% and was closed at $30.58. REV EPS growth in last 5 year was -4.20%. Revlon, Inc. (NYSE:REV) year to date (YTD) performance is -10.48%.

Revlon, Inc., through its subsidiary, Revlon Consumer Products Corporation and its subsidiaries, manufactures, markets and sells a range of beauty and personal care products, including cosmetics, hair color, hair care and hair treatments, beauty tools, men’s grooming products, anti-perspirant deodorants, fragrances, skincare and other beauty care products. The Company operates through two segments: the Consumer segment and the Professional segment.

Revlon on Tuesday kicked off its Love is On Million Dollar Challenge, which looks to raise money for more than 100 women’s health charities. At the end of the challenge, the organization with the most donations from Revlon customers will be eligible for a $1 million contribution from Revlon, with the runner-up receiving $250,000. Over the course of the six-week challenge, Revlon will also distribute $150,000 a week in bonus challenge money.

United States Steel Corp. (NYSE:X) shares fell -6.01% in last trading session and ended the day at $10.79. X Gross Margin is 11.10% and its has a return on assets of -2.30%. United States Steel Corp. (NYSE:X) quarterly performance is -49.92%.

United States Steel Corporation (U. S. Steel) is a steel producer. The Company is engaged in producing flat-rolled and tubular products with production operations in North America and Europe. The Company operates through three segments: Flat-rolled Products (Flat-rolled), U. S. Steel Europe (USSE) and Tubular Products (Tubular).

The United Steelworkers and representatives from United States Steel Corp. (NYSE:X) resume contract talks in Pittsburgh Sept. 27, according to an update from the union. The USW said the parties remain far apart on key issues, but no additional details were provided. A representative of the union declined to provide additional comment.

Omeros Corporation (NASDAQ:OMER) caters to the Healthcare space. Its weekly performance is -13.17%. On the last day of trading company shares ended up at $11.80. Omeros Corporation (NASDAQ:OMER) distance from 50-day simple moving average (SMA50) is -24.14%.

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.

Omeros Corporation (NASDAQ:OMER) released that it has filed patent infringement court cases against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC, in the U.S. District Court for the District of New Jersey and in the U.S. District Court for the District of Delaware. The court cases were filed under the Hatch-Waxman Act for Par’s infringement of three Omeros patents, U.S. Patent Nos. 8,173,707, 8,586,633 and 9,066,856, which relate to Omeros’ drug Omidria 1%/0.3percentage and which are listed in the Agreed Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book, published by the U.S. Food and Drug Administration.